54 results on '"Stein, Mark A."'
Search Results
2. A new schizophrenia screening instrument based on evaluating the patient's writing
3. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
4. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial
5. Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer
6. Sleep habits in children with attention-deficit/hyperactivity disorder predominantly inattentive type and associations with comorbid psychopathology symptoms
7. Editorial: Attention-Deficit/Hyperactivity Disorder, Stimulant Medication, and Criminality: Commentary and Caution.
8. Editorial: Treating Attention-Deficit/Hyperactivity Disorder in Preschool-Age Children With Stimulants: Modest Effects in Young Children With Big Problems.
9. 41.1 Understanding the Impact of ADHD Familiality and Genetics on ADHD Medication Response and Optimization.
10. Editorial: Longitudinal Associations Between Sleep and ADHD Symptoms: ADHD Is a 24-Hour Disorder.
11. Reducing Anesthesia Use for Pediatric Magnetic Resonance Imaging: The Effects of a Patient- and Family-Centered Intervention on Image Quality, Health-care Costs, and Operational Efficiency.
12. NEUROPHYSIOLOGY OF ADHD IN EEG, EYE TRACKING, PUPIL RESPONSE, BREADTH OF PERCEPTION, AND NEUROFEEDBACK AND TRIGEMINAL NERVE STIMULATION (TNS) EFFECTS: NEW ICAN AND OTHER DATA.
13. Feedback associated with expectation for larger-reward improves visuospatial working memory performances in children with ADHD.
14. MANAGING ADOLESCENTS WITH ADHD: DEVELOPMENTAL ISSUES, EMERGING COMORBIDITY, AND THE IMPACT OF COVID-19.
15. Editorial: Is Less Parent Training "Not Inferior" to More?
16. BARRIERS AND SOLUTIONS TO TREATING TEENAGERS WITH ADHD: PERSPECTIVES FROM CLINICAL RESEARCHERS.
17. 9.1 A SHARED DECISION-MAKING APPROACH TO EVALUATING, SEQUENCING, AND COMBINING INTERVENTIONS IN TEENAGERS WITH ADHD.
18. Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) has a positive safety and tolerability profile in an open-label, multicenter, phase 3 study in primary immunodeficiency (PI).
19. Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) is effective in primary humoral immunodeficiency (PI): results from a prospective, open-label, multicenter, phase 3 study.
20. Predictors of Treatment Engagement and Outcome Among Adolescents With Attention-Deficit/Hyperactivity Disorder: An Integrative Data Analysis.
21. Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases.
22. Ig20Gly Tolerability and Infusion Characteristics in Pediatric and Advanced Age Patients With Primary Immunodeficiency Diseases.
23. 20% subcutaneous immunoglobulin dosed biweekly for primary immunodeficiency.
24. 25.3 A Pilot Smart Targeting Multiplex ADHD Families: Lessons Learned.
25. 7.2 Losing Sleep Over ADHD and Stimulants?
26. Onboarding Experience of Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin 10%.
27. Response to Crizotinib in a Patient with MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib.
28. 42.3 Diagnostic Dilemmas With Subclinical or Mild Attention-Deficit/Hyperactivity Disorder.
29. 855 - Response to Methylphenidate and Atomoxetine in Children with ADHD: Pharmacogenetic Predictors.
30. A New Liquid 10% Intravenous Immunoglobulin (IVIG) Administered with 15-Minute Titration Periods Allows Shorter Infusion Durations and Tolerability Similar to a 5% Formulation.
31. Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs).
32. Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive Studies.
33. Modified Oral Rapid Drug Desensitization (ORDD) to Ibrutinib in a Patient with Stage IV Mantle Cell Lymphoma and Early Onset Grade 1 Hypersensitivity Reaction.
34. A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America.
35. Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (IGHy) in Patients with Primary Immunodeficiency Disease (PIDD): Infections over Time.
36. Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America.
37. Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies.
38. Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study.
39. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder.
40. Telemedicine in management of genitourinary malignancies: Patient and physician perspectives.
41. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
42. Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.
43. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.
44. A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802.
45. Dopamine Transporter and CYP2D6 Genotype Associations With ADHD Treatment Response: Results From the Methylphenidate-Atomoxetine Crossover Study (MACRO).
46. 5.16 LIFESTYLE ENHANCEMENT FOR ADHD PROGRAM (LEAP): HEALTH-FOCUSED PARENT TRAINING INTERVENTION EFFECTS ON PHYSICAL ACTIVITY AND SCREEN TIME BEHAVIORS AMONG CHILDREN WITH ADHD.
47. 6.36 Comparing Health Behaviors in Youth With Neurodevelopmental Disorders vs. Asthma or Normative Controls.
48. Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine.
49. 856 - Methylphenidate vs. Atomoxetine in Youth with ADHD: Comparative Effectiveness and Preference following Treatment with both Medications.
50. 6.40 EXAMINATION OF THE SLUGGISH COGNITIVE TEMPO CONSTRUCT IN PEDIATRIC ATTENTION-DEFICIT/HYPERACTIVITY DISORDER.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.